• 文献检索
  • 文档翻译
  • 深度研究
  • 学术资讯
  • Suppr Zotero 插件Zotero 插件
  • 邀请有礼
  • 套餐&价格
  • 历史记录
应用&插件
Suppr Zotero 插件Zotero 插件浏览器插件Mac 客户端Windows 客户端微信小程序
定价
高级版会员购买积分包购买API积分包
服务
文献检索文档翻译深度研究API 文档MCP 服务
关于我们
关于 Suppr公司介绍联系我们用户协议隐私条款
关注我们

Suppr 超能文献

核心技术专利:CN118964589B侵权必究
粤ICP备2023148730 号-1Suppr @ 2026

文献检索

告别复杂PubMed语法,用中文像聊天一样搜索,搜遍4000万医学文献。AI智能推荐,让科研检索更轻松。

立即免费搜索

文件翻译

保留排版,准确专业,支持PDF/Word/PPT等文件格式,支持 12+语言互译。

免费翻译文档

深度研究

AI帮你快速写综述,25分钟生成高质量综述,智能提取关键信息,辅助科研写作。

立即免费体验

去甲替林的E型和Z型10-羟基化作用:与异喹胍多态性羟基化作用的关系。

E- and Z-10-hydroxylation of nortriptyline: relationship to polymorphic debrisoquine hydroxylation.

作者信息

Mellström B, Bertilsson L, Säwe J, Schulz H U, Sjöqvist F

出版信息

Clin Pharmacol Ther. 1981 Aug;30(2):189-93. doi: 10.1038/clpt.1981.147.

DOI:10.1038/clpt.1981.147
PMID:7249504
Abstract

Eight healthy subjects [who were phenotyped with a debrisoquine (D) hydroxylation test] were selected to cover a wide range in the ratio between D and 4-hydroxydebrisoquine (4-OH-D) in the urine. After a single oral dose of nortriptyline (NT) the metabolic clearance by 10-hydroxylation in the E-position, but not in the Z-position, correlated closely to the metabolic ratio D/4-OH-D (rs = -0.88, p less than 0.01). This indicates that common enzymatic mechanisms are involved in the hydroxylation of D and the E- but not the Z-10-hydroxylation of NT. Slow hydroxylators of NT and D excreted less 10-hydroxynortriptyline in urine and had lower plasma clearance of NT than the rapid hydroxylators. The strong correlation (r = 0.96) between the total plasma clearance of NT and the metabolic clearance by E-10-hydroxylation shows that this metabolic reaction is important in the disposition of the drug.

摘要

选取了8名健康受试者[通过异喹胍(D)羟基化试验进行表型分析],以涵盖尿液中D与4 - 羟基异喹胍(4 - OH - D)比值的广泛范围。单次口服去甲替林(NT)后,E位而非Z位的10 - 羟基化代谢清除率与代谢比值D/4 - OH - D密切相关(rs = -0.88,p小于0.01)。这表明D的羟基化与NT的E - 10 - 羟基化而非Z - 10 - 羟基化涉及共同的酶促机制。NT和D的慢羟基化者尿液中排泄的10 - 羟基去甲替林较少,且NT的血浆清除率低于快羟基化者。NT的总血浆清除率与E - 10 - 羟基化代谢清除率之间的强相关性(r = 0.96)表明,这种代谢反应在药物处置中很重要。

相似文献

1
E- and Z-10-hydroxylation of nortriptyline: relationship to polymorphic debrisoquine hydroxylation.去甲替林的E型和Z型10-羟基化作用:与异喹胍多态性羟基化作用的关系。
Clin Pharmacol Ther. 1981 Aug;30(2):189-93. doi: 10.1038/clpt.1981.147.
2
Nortriptyline and debrisoquine hydroxylations in Ghanaian and Swedish subjects.
Clin Pharmacol Ther. 1984 Sep;36(3):374-8. doi: 10.1038/clpt.1984.190.
3
Plasma concentrations of nortriptyline and its 10-hydroxy metabolite in depressed patients--relationship to the debrisoquine hydroxylation metabolic ratio.抑郁症患者体内去甲替林及其10-羟基代谢物的血浆浓度——与异喹胍羟化代谢率的关系。
Br J Clin Pharmacol. 1985 Jun;19(6):832-5. doi: 10.1111/j.1365-2125.1985.tb02723.x.
4
Correlation between nortriptyline and debrisoquine hydroxylation in the human liver.
Life Sci. 1983 Aug 15;33(7):631-6. doi: 10.1016/0024-3205(83)90251-5.
5
Hydroxylation of desmethylimipramine: dependence on the debrisoquin hydroxylation phenotype.
Clin Pharmacol Ther. 1987 Mar;41(3):314-9. doi: 10.1038/clpt.1987.33.
6
Phenotypic consistency in hydroxylation of desmethylimipramine and debrisoquine in healthy subjects and in human liver microsomes.健康受试者及人肝微粒体中去甲丙咪嗪和异喹胍羟化作用的表型一致性。
Clin Pharmacol Ther. 1984 Nov;36(5):677-82. doi: 10.1038/clpt.1984.239.
7
Nortriptyline and antipyrine clearance in relation to debrisoquine hydroxylation in man.人体内去甲替林和安替比林清除率与异喹胍羟化作用的关系。
Life Sci. 1980 Nov 3;27(18):1673-7. doi: 10.1016/0024-3205(80)90642-6.
8
Codeine O-demethylation co-segregates with polymorphic debrisoquine hydroxylation.可待因O-去甲基化与多态性异喹胍羟基化共分离。
Br J Clin Pharmacol. 1989 Dec;28(6):639-45. doi: 10.1111/j.1365-2125.1989.tb03556.x.
9
Oxidation of tricyclic antidepressant drugs, debrisoquine and 7-ethoxyresorufin, by human liver preparations.人肝制剂对三环类抗抑郁药、去甲异喹胍和7-乙氧基试卤灵的氧化作用。
Xenobiotica. 1986 May;16(5):391-400. doi: 10.3109/00498258609050247.
10
[Relationship between amitriptyline metabolism and polymorphic debrisoquine hydroxylation in native Chinese volunteers].
Yao Xue Xue Bao. 1993;28(2):85-91.

引用本文的文献

1
Validating the accuracy of mathematical model-based pharmacogenomics dose prediction with real-world data.利用真实世界数据验证基于数学模型的药物基因组学剂量预测的准确性。
Eur J Clin Pharmacol. 2025 Mar;81(3):451-462. doi: 10.1007/s00228-025-03805-x. Epub 2025 Jan 17.
2
Pharmacogenetics in Primary Headache Disorders.原发性头痛疾病中的药物遗传学
Front Pharmacol. 2022 Feb 10;12:820214. doi: 10.3389/fphar.2021.820214. eCollection 2021.
3
CYP2D6 polymorphisms and their influence on risperidone treatment.CYP2D6基因多态性及其对利培酮治疗的影响。
Pharmgenomics Pers Med. 2016 Dec 1;9:131-147. doi: 10.2147/PGPM.S107772. eCollection 2016.
4
The Role of Metabolites of Antidepressants in the Treatment of Depression.抗抑郁药代谢物在抑郁症治疗中的作用。
CNS Drugs. 1997 Apr;7(4):273-312. doi: 10.2165/00023210-199707040-00003.
5
Pharmacokinetic interaction between nevirapine and nortriptyline in rats: inhibition of nevirapine metabolism by nortriptyline.奈韦拉平与去甲替林在大鼠体内的药代动力学相互作用:去甲替林对奈韦拉平代谢的抑制作用
Antimicrob Agents Chemother. 2014 Dec;58(12):7041-8. doi: 10.1128/AAC.03312-14. Epub 2014 Sep 15.
6
Antidepressant-induced akathisia-related homicides associated with diminishing mutations in metabolizing genes of the CYP450 family.抗抑郁药诱发的静坐不能相关杀人行为与细胞色素P450(CYP450)家族代谢基因的突变减少有关。
Pharmgenomics Pers Med. 2011;4:65-81. doi: 10.2147/PGPM.S17445. Epub 2011 Aug 1.
7
Polymorphism of human cytochrome P450 2D6 and its clinical significance: part II.人细胞色素 P450 2D6 的多态性及其临床意义:第二部分。
Clin Pharmacokinet. 2009;48(12):761-804. doi: 10.2165/11318070-000000000-00000.
8
The CYP2D6 polymorphism in relation to the metabolism of amitriptyline and nortriptyline in the Faroese population.法罗群岛人群中细胞色素P450 2D6基因多态性与阿米替林和去甲替林代谢的关系。
Br J Clin Pharmacol. 2008 Jan;65(1):134-8. doi: 10.1111/j.1365-2125.2007.02969.x. Epub 2007 Aug 31.
9
3,4-Dehydrodebrisoquine, a novel debrisoquine metabolite formed from 4-hydroxydebrisoquine that affects the CYP2D6 metabolic ratio.3,4-脱氢去甲丙咪嗪,一种由4-羟基去甲丙咪嗪形成的新型去甲丙咪嗪代谢物,它会影响CYP2D6代谢率。
Drug Metab Dispos. 2006 Sep;34(9):1563-74. doi: 10.1124/dmd.105.008920. Epub 2006 Jun 16.
10
Disposition of debrisoquine and nortriptyline in Korean subjects in relation to CYP2D6 genotypes, and comparison with Caucasians.韩国人群中与CYP2D6基因型相关的异喹胍和去甲替林的处置情况,以及与高加索人的比较。
Br J Clin Pharmacol. 2003 Jun;55(6):630-4. doi: 10.1046/j.1365-2125.2003.01804.x.